Pharmaceuticals company Granules India announced Q2FY26 results Revenue from Operations of Q2FY26 stood at Rs 12,970 million, a growth of 34% YoY across regions. EBITDA: Rs 2,782 million against Rs 2,033 million during Q2FY25, change 37%. EBITDA Margin: 21% for Q2FY26. PBT: Rs 1,759 million against Rs 1,284 million during Q2FY25, change 37%. PAT: Rs 1,306 million against Rs 972 million during Q2FY25, change 34%. PAT Margin: 10% for Q2FY26. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said: “We are delighted to deliver a resilient financial performance with healthy growth in both revenue and profitability. The improvement in EBITDA and PAT reflects our continued focus on operational excellence, disciplined execution, and the strength of our governance. Our ongoing investments in R&D; and talent underscore our commitment to innovation and long-term value creation. Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway.” Result PDF
